FOOD AND DRUG ADMINISTRATION (FDA)
Center for Drug Evaluation and Research (CDER)

Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) Meeting
FDA White Oak Campus, Building 31 Conference Center, the Great Room (Rm. 1503)
10903 New Hampshire Avenue, Silver Spring, Maryland
October 24 – 25, 2018

MEETING ROSTER

DESIGNATED FEDERAL OFFICER (Non-Voting)

LaToya Bonner, PharmD, NCPS
Division of Advisory Committee and Consultant Management
Office of Executive Programs, CDER, FDA

ENDOCRINOLOGIC AND METABOLIC DRUGS ADVISORY COMMITTEE MEMBERS (Voting)

Michael Blaha, MD, MPH
Associate Professor, Cardiology and Epidemiology
Director of Clinical Research
Johns Hopkins Ciccarone Center for the Prevention of Heart Disease
Baltimore, Maryland

Daniel Budnitz, MD, MPH
CAPT, US Public Health Service
Director, Medication Safety Program
Division of Healthcare Quality Promotion
Centers for Disease Control and Prevention
Atlanta, Georgia

Kenneth D. Burman, MD
Chief, Endocrine Section
Medstar Washington Hospital Center
Professor, Department of Medicine
Georgetown University
Washington, District of Columbia

James de Lemos, MD
Professor of Medicine
Sweetheart Ball/Kern Wildenthal, MD, PhD
Distinguished Chair in Cardiology
UT Southwestern Medical Center
Dallas, Texas

Susan S. Ellenberg, PhD
Professor of Biostatistics
Professor of Medical Ethics and Health Policy (secondary)
Department of Biostatistics, Epidemiology and Informatics
Perelman School of Medicine
University of Pennsylvania
Philadelphia, Pennsylvania

Cecilia C. Low Wang, MD
Associate Professor of Biostatistics
Director, Glucose Management Team
University of Colorado Hospital
Department of Medicine, Division of Endocrinology, Metabolism and Diabetes
University of Colorado Anschutz Medical Campus
School of Medicine
Lead Clinician-Scientist, CPC Clinical Research
Aurora, Colorado

Anna McCollister-Slipp
(Consumer Representative)
Founder, VitalCrowd
Washington, District of Columbia

Peter W. F. Wilson, MD
(Chairperson)
Director, Epidemiology and Genomic Medicine
Atlanta Veterans Administration Medical Center
Professor of Medicine and Public Health
Emory University
Emory Clinical Cardiovascular Research Institute
Atlanta, Georgia
ENDOCRINOLOGIC AND METABOLIC DRUGS ADVISORY COMMITTEE MEMBERS (Voting) (cont.)

Susan Z. Yanovski, MD
Co-Director, Office of Obesity Research
Senior Scientific Advisor for Clinical Obesity Research
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
National Institutes of Health (NIH)
Bethesda, Maryland

TEMPORARY MEMBERS (Voting)

Brendan M. Everett, MD, MPH
Assistant Professor of Medicine
Harvard Medical School
Director, General Cardiology Inpatient Service
Brigham and Women’s Hospital
Boston, Massachusetts

Judith Fradkin, MD
Director, Division of Diabetes, Endocrinology, and Metabolic Diseases
NIDDK, NIH
Bethesda, Maryland

Fred Kushner, MD, FACC
Clinical Professor of Medicine
Louisiana State University Medical Center
Clinical Professor of Medicine at Tulane University
Adjunct Professor of Medicine
New York University
Langone Health
New York, New York

George Grunberger, MD, FACP, FACE
Chairman, Grunberger Diabetes Institute
Bloomfield Hills, Michigan
Clinical Professor, Internal Medicine and Molecular Medicine & Genetics
Wayne State University School of Medicine
Professor, Internal Medicine
Oakland University William Beaumont School of Medicine
Visiting Professor, Internal Medicine
First Faculty of Medicine, Charles University
Prague, Czech Republic

Richard Dan Lumley (Patient Representative)
Kansas, Missouri

Martha Nason, PhD
Mathematical Statistician
Biostatistics Branch
National Institute of Allergy and Infectious Diseases, NIH
Bethesda, Maryland
TEMPORARY MEMBERS (Voting) (cont.)

Connie B. Newman, MD, FACP, FAHA, FAMWA
Adjunct Professor, Department of Medicine
Division of Endocrinology, Diabetes and Metabolism
New York University School of Medicine
New York, New York

David C. Robbins, MD
Professor of Medicine
Director, University of Kansas Diabetes Institute
University of Kansas School of Medicine
Kansas City, Kansas

Yves Rosenberg, MD, MPH
Chief, Atherothrombosis and Coronary Artery Disease Branch
Division of Cardiovascular Sciences
National Heart, Lung and Blood Institute, NIH
Bethesda, Maryland

Thomas J. Wang, MD
Professor of Medicine
Gottlieb C. Friesinger II Chair in Cardiovascular Medicine
Director, Division of Cardiovascular Medicine
Physician-in-Chief
Vanderbilt Heart & Vascular Institute
Vanderbilt University Medical Center
Nashville, Tennessee

ACTING INDUSTRY REPRESENTATIVE TO THE COMMITTEE (Non-Voting)

Scott Wasserman, MD, FACC
(Acting Industry Representative)
Vice President, Global Development
Head, Cardiovascular, Metabolic, and Neuroscience Therapeutic Areas
Amgen, Inc.
Thousand Oaks, California

FDA PARTICIPANTS (Non-Voting)

Mary Thanh Hai, MD
Director (Acting)
Office of Drug Evaluation II (ODE-II)
Office of New Drugs (OND), CDER, FDA

William Chong, MD
Director (Acting)
Division of Metabolism and Endocrinology Products (DMEP)
ODE-II, OND, CDER, FDA

Lisa Yanoff, MD
Deputy Director (Acting)
DMEP, ODE-II, OND, CDER, FDA

Patrick Archdeacon, MD
Clinical Team Lead
DMEP, ODE-II, OND, CDER, FDA

Mahtab Niyati, MD
Clinical Reviewer
DMEP, ODE-II, OND, CDER, FDA